Skip to main content
Download PDF

Volume 3 Supplement 2

30th Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2015)

Lower toxicity and higher efficacy: a study on a novel fully human anti-EGFR antibody

Journal for ImmunoTherapy of Cancer volume 3, Article number: P241 (2015) Cite this article

We generated a novel fully human anti-EGFR antibody showed lower toxicity and higher efficacy in the preclinical, toxicological and pharmacological studies when compared to a commercial drug Cetuximab. In this research, we aimed to understand the probably mechanism.

Firstly, the mAb prefers binding to higher expression of EGFR. Its binding avidity on IgG form of the mAb to EGFR was equivalent to Cetuximab, while the Fab affinity was significantly lower. As a result, Higher EGFR expression tissues like tumor obtained the equivalent efficacy as Erbitux, while normal tissues with lower EGFR expression consequently showed lower toxicity.

Secondly, the new mAb had higher concentration in tumor tissue than Erbitux. The accumulation of antibody in tumor local might induce stronger ADCC effect, and resulted in higher anti-tumor efficacy than Erbitux in a Hu-WBC NOD SCID xenograft mice model.

Author information

Authors and Affiliations

  1. Institute of Biotechnology, Academy of Military Medical Sciences, Beijing, People's Republic of China

    Weiyi Qiu & Shuang Wang

Authors
  1. Weiyi Qiu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Shuang Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Qiu, W., Wang, S. Lower toxicity and higher efficacy: a study on a novel fully human anti-EGFR antibody. j. immunotherapy cancer 3 (Suppl 2), P241 (2015). https://doi.org/10.1186/2051-1426-3-S2-P241

Download citation

  • Published:

  • DOI: https://doi.org/10.1186/2051-1426-3-S2-P241

Keywords

  • Cetuximab
  • Lower Toxicity
  • Xenograft Mouse Model
  • Lower EGFR
  • EGFR Expression